Skip to content
ClinCalc Pro
Menu
Centrally acting α2A agonist

Guanfacine

Brand names: Intuniv

Guanfacine is a selective alpha-2A adrenergic agonist licensed for attention deficit hyperactivity disorder (ADHD) in children and young people.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It stimulates postsynaptic alpha-2A adrenoceptors in the prefrontal cortex, strengthening regulation of attention and behaviour; this central sympathetic modulation also lowers blood pressure.

Prescribing in practice

  • It can cause hypotension, bradycardia and sedation, and abrupt withdrawal may produce rebound hypertension, so it must be tapered rather than stopped suddenly.
  • Blood pressure, heart rate and weight should be assessed before and during treatment, with caution where there is cardiovascular disease.
  • Sedation and effects on blood pressure are increased by other CNS depressants and antihypertensives; dosing for children should follow a children's formulary.

Monitoring

Monitor blood pressure, heart rate, weight and somnolence at baseline and periodically during treatment and on dose change.

Counselling the patient

  • May cause drowsiness, especially when starting; take care with activities needing alertness.
  • Do not stop the medicine suddenly as blood pressure can rise; reduce gradually as advised.
  • Report fainting, dizziness or a very slow heartbeat.

Evidence & guidelines

Guanfacine is recommended by NICE as a non-stimulant option for ADHD in children and young people where stimulants are unsuitable or ineffective.

Reference: NICE NG87; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.